Autopsy report · NCT02718677

Patient-reported Outcomes in Subjects Treated With ReFacto AF Routine Prophylaxis

“Company decision to not conduct study”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Sponsor

Pfizer

Sponsor type

Industry

Conditions

Hemophilia A

Interventions

Refacto AF

Participants

0

Trials that died the same way

• Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma
  “Company decision not to start the study” (85% match in meaning)
• Plaque Removal Versus Open Bypass Surgery For Critical Limb Ischemia
  “Company decision to halt study” (77% match in meaning)
• TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88)
  “Company operational decision. Decision to stop study is not due to safety or efficacy concerns.” (75% match in meaning)
• Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
  “Decision was made to not go forward with the study” (75% match in meaning)
• Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
  “Study was never initiated due to company decision. No study subjects were ever enrolled or treated.” (73% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.